PEE1
MCID: PRC031
MIFTS: 41

Preeclampsia/eclampsia 1 (PEE1)

Categories: Blood diseases, Genetic diseases

Aliases & Classifications for Preeclampsia/eclampsia 1

MalaCards integrated aliases for Preeclampsia/eclampsia 1:

Name: Preeclampsia/eclampsia 1 58 13
Preeclampsia/eclampsia, Type 1 41
Toxemia of Pregnancy 58
Pre-Eclampsia 74
Preg1 58
Pee1 58
Pee 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant

Miscellaneous:
majority of cases are sporadic
occurs in ~3% pregnancies in western populations
clinical manifestation ranges from mild, transient hypertension to hellp syndrome (hemolysis, elevated liver enzymes, and low platelets)


HPO:

33
preeclampsia/eclampsia 1:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Preeclampsia/eclampsia 1

OMIM : 58 Preeclampsia, which along with chronic hypertension and gestational hypertension comprise the hypertensive disorders of pregnancy, is characterized by new hypertension (blood pressure 140/90 or greater) presenting after 20 weeks' gestation with clinically relevant proteinuria. Preeclampsia is 1 of the top 4 causes of maternal mortality and morbidity worldwide (summary by Payne et al., 2011). Preeclampsia is otherwise known as gestational proteinuric hypertension (Davey and MacGillivray, 1988). A high proportion of patients with preeclampsia have glomerular endotheliosis, the unique histopathologic feature of the condition (Fisher et al., 1981). A distinct form of severe preeclampsia is characterized by hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome) (Brown et al., 2000). (189800)

MalaCards based summary : Preeclampsia/eclampsia 1, also known as preeclampsia/eclampsia, type 1, is related to pre-eclampsia and eclampsia, and has symptoms including edema and hyperemesis gravidarum. An important gene associated with Preeclampsia/eclampsia 1 is NSD1 (Nuclear Receptor Binding SET Domain Protein 1). The drugs Methyldopa and Calcium Carbonate have been mentioned in the context of this disorder. Affiliated tissues include endothelial, testes and placenta, and related phenotypes are hypertension and seizures

Related Diseases for Preeclampsia/eclampsia 1

Graphical network of the top 20 diseases related to Preeclampsia/eclampsia 1:



Diseases related to Preeclampsia/eclampsia 1

Symptoms & Phenotypes for Preeclampsia/eclampsia 1

Human phenotypes related to Preeclampsia/eclampsia 1:

33 (show all 10)
# Description HPO Frequency HPO Source Accession
1 hypertension 33 HP:0000822
2 seizures 33 HP:0001250
3 proteinuria 33 HP:0000093
4 edema 33 HP:0000969
5 intrauterine growth retardation 33 HP:0001511
6 elevated hepatic transaminase 33 HP:0002910
7 thrombocytopenia 33 HP:0001873
8 preeclampsia 33 HP:0100602
9 eclampsia 33 HP:0100601
10 maternal hypertension 33 HP:0008071

Symptoms via clinical synopsis from OMIM:

58
Genitourinary Kidneys:
proteinuria

Muscle Soft Tissue:
edema

Cardiovascular Vascular:
maternal hypertension (after 20th week gestation, resolved postpartum)

Abdomen Liver:
elevated liver enzymes

Hematology:
thrombocytopenia (hellp syndrome)

Laboratory Abnormalities:
proteinuria
elevated liver enzymes

Growth Other:
intrauterine growth retardation (in fetus)

Prenatal Manifestations Maternal:
maternal hypertension (after 20th week gestation, resolved postpartum)

Neurologic Central Nervous System:
seizures (eclampsia)

Clinical features from OMIM:

189800

UMLS symptoms related to Preeclampsia/eclampsia 1:


edema, hyperemesis gravidarum

Drugs & Therapeutics for Preeclampsia/eclampsia 1

Drugs for Preeclampsia/eclampsia 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 462)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyldopa Approved Phase 4,Phase 2,Phase 1,Not Applicable 555-30-6 38853
2
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Not Applicable 471-34-1
3
Remifentanil Approved Phase 4,Phase 2,Phase 1 132875-61-7 60815
4
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68-04-2
5
Metformin Approved Phase 4,Phase 2,Phase 3,Not Applicable 657-24-9 14219 4091
6
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
7
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772
8
Dalteparin Approved Phase 4,Phase 2,Phase 3,Early Phase 1 9005-49-6
9
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 9005-49-6 46507594 772
10
leucovorin Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
11
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-56-6 53477758 439302
12
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6 32051
13
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 90-82-4 7028
14
Phenylephrine Approved Phase 4,Not Applicable 59-42-7 6041
15
Ephedrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 299-42-3 9294
16
Oxymetazoline Approved, Investigational Phase 4,Not Applicable 1491-59-4 4636
17
Misoprostol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 59122-46-2 5282381
18
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7487-88-9 24083
19
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
20
Furosemide Approved, Vet_approved Phase 4,Phase 2 54-31-9 3440
21
Clonidine Approved Phase 4,Phase 1,Phase 2,Not Applicable 4205-90-7 2803
22
Captopril Approved Phase 4 62571-86-2 44093
23
Ibuprofen Approved Phase 4,Phase 2,Phase 3,Not Applicable 15687-27-1 3672
24
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Not Applicable 103-90-2 1983
25
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
26
Nifedipine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 21829-25-4 4485
27
Labetalol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36894-69-6 3869
28
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
29
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
30
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
31
Insulin Aspart Approved Phase 4,Phase 3,Not Applicable 116094-23-6 16132418
32
Insulin Lispro Approved Phase 4,Not Applicable 133107-64-9
33
Glyburide Approved Phase 4,Not Applicable 10238-21-8 3488
34
Azithromycin Approved Phase 4,Phase 3,Not Applicable 83905-01-5 447043 55185
35
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
36
Warfarin Approved Phase 4 81-81-2 54678486 6691
37
Insulin Detemir Approved Phase 4,Phase 3,Not Applicable 169148-63-4 5311023
38
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
39
Desogestrel Approved Phase 4 54024-22-5 40973
40
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-70-2 271
41
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
43
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 67-97-0 5280795 6221
44
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1406-16-2
45
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1,Phase 2,Not Applicable 50-14-6 5280793
46
Serine Approved, Nutraceutical Phase 4,Phase 3,Early Phase 1,Not Applicable 56-45-1 5951
47 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Bone Density Conservation Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
50 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 786)
# Name Status NCT ID Phase Drugs
1 Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape) Unknown status NCT01361425 Phase 4 methildopa;placebo
2 Low Dose Calcium to Prevent Preeclampsia Unknown status NCT02338687 Phase 4
3 Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia Unknown status NCT00117546 Phase 4 alpha methyldopa
4 Remifentanil for General Anesthesia in Preeclamptics Unknown status NCT00567957 Phase 4 Remifentanil;Saline
5 Viagra for the Treatment of IUGR Unknown status NCT00347867 Phase 4 Viagra administration in IUGR/PET pregnancies
6 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
7 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4 Aspirin;Placebo
8 Treatment Approaches to Preeclampsia Completed NCT01030627 Phase 4
9 Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia Completed NCT02699827 Phase 4 Levobupivacaine hydrochloride;Magnesium sulphate;Saline 0.9%
10 Diuretics for Postpartum High Blood Pressure in Preeclampsia Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
11 Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
12 Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
13 Trial of Early Screening Test for Pre-eclampsia and Growth Restriction Completed NCT03674606 Phase 4 Low dose aspirin
14 A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
15 Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
16 The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy Completed NCT02891174 Phase 4 Ibuprofen;Acetaminophen
17 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients Completed NCT01972659 Phase 4 placebo;Magnesium Sulphate;sugammadex
18 Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy Completed NCT01912677 Phase 4 Nifedipine;Labetalol;Methyldopa
19 Enoxaparin in the Prevention of Placental Insufficiency in Pregnant Women Completed NCT03528967 Phase 4 Enoxaparin 40 mg / 0.4 mL Prefilled Syringe;Aspirin 100 mg Oral Tablet, Enteric Coated
20 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
21 Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT Completed NCT00790062 Phase 4 Oxytocin
22 Timing of Initiation of LMWH Administration in Pregnant Women With APS Completed NCT02326051 Phase 4 Enoxaparin;Enoxaparin
23 Preterm Infant Inhaled Albuterol Dosing Completed NCT02447250 Phase 4 Varied albuterol dose response
24 Metformin Versus Insulin in Gestational Diabetes Completed NCT01240785 Phase 4 metformin;insulin
25 Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients Completed NCT02466204 Phase 4 corifollitropin alfa;Follitropin Beta
26 Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo Completed NCT00744965 Phase 4 Glyburide;Placebo
27 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
28 The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia Recruiting NCT03735433 Phase 4 162mg aspirin dose
29 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Recruiting NCT03233880 Phase 4 Azithromycin 1gm
30 Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia Recruiting NCT03164304 Phase 4 Magnesium Sulfate
31 Phenylephrine Versus Ephedrine in Pre-eclampsia Recruiting NCT02025426 Phase 4 Phenylephrine;Ephedrine
32 Acute Labetalol Use in Preeclampsia Recruiting NCT03872336 Phase 4 Experimental labetalol dose
33 Early Vascular Adjustments During Hypertensive Pregnancy Recruiting NCT02531490 Phase 4 Labetalol;Nifedipine;Methyldopa
34 Acute Control of Chronic Hypertension Recruiting NCT03877692 Phase 4 Experimental dosing of labetalol
35 Oral Nifedipine Versus Labetalol in Treatment of Postpartum Hypertension Recruiting NCT03449277 Phase 4 Oral Tablet
36 Response to Anti-hypertensives in Pregnant and Postpartum Patients Recruiting NCT03506724 Phase 4 Nifedipine;Labetalol
37 Postpartum NSAIDS and Maternal Hypertension Recruiting NCT03824119 Phase 4 Ibuprofen 600 mg
38 Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily? Recruiting NCT03595982 Phase 4 Procardia XL 30Mg;Procardia XL 60Mg
39 Chronotherapy With Low-dose Aspirin for Primary Prevention Recruiting NCT00725127 Phase 4 aspirin;aspirin
40 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Recruiting NCT02920593 Phase 4 Vitamin D3
41 Chronic Hypertension and Pregnancy (CHAP) Project Recruiting NCT02299414 Phase 4 Anti-hypertensive therapy
42 Use of Warfarin After the First Trimester in Pregnant Women With APS Recruiting NCT02303171 Phase 4 Enoxaparin;Warfarin
43 Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology Recruiting NCT03177122 Phase 4 Myo-inositol
44 Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Recruiting NCT03620890 Phase 4 Neutral Protamine Hagedorn (NPH);Detemir insulin
45 A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor Recruiting NCT02777190 Phase 4 Misoprostol
46 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Active, not recruiting NCT02911701 Phase 4 Acetaminophen;Ibuprofen
47 Contraception in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
48 Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Not yet recruiting NCT03318211 Phase 4 Magnesium Sulfate
49 Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus Not yet recruiting NCT03570632 Phase 4 Metformin
50 Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients Not yet recruiting NCT03237000 Phase 4 MgSO4

Search NIH Clinical Center for Preeclampsia/eclampsia 1

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Preeclampsia/eclampsia 1

Anatomical Context for Preeclampsia/eclampsia 1

MalaCards organs/tissues related to Preeclampsia/eclampsia 1:

42
Endothelial, Testes, Placenta, Thyroid, Heart, Brain, Ovary

Publications for Preeclampsia/eclampsia 1

Articles related to Preeclampsia/eclampsia 1:

(show all 30)
# Title Authors Year
1
A study of intravaginal misoprostol for induction of labor in toxemia of pregnancy. ( 11597613 )
2001
2
[Bilateral retinal detachment in toxemia of pregnancy]. ( 10526447 )
1999
3
[Changes in serum lipoprotein (a) levels related to hyperlipidemia during pregnancy--comparing normal pregnancy and toxemia of pregnancy]. ( 8721051 )
1996
4
Retinal pigment epithelium tear following toxemia of pregnancy. ( 7549444 )
1995
5
The relationship between clinical signs and hypercoagulable state in toxemia of pregnancy. ( 1828053 )
1991
6
[Blood coagulation and fibrinolytic studies in patients with toxemia of pregnancy]. ( 2273312 )
1990
7
Changes in placental atrial natriuretic peptide receptors associated with severe toxemia of pregnancy. ( 2543965 )
1989
8
Theory of the etiology of human toxemia of pregnancy: fetal hyperinsulinemia as a compensatory response to decreased uterine blood flow. ( 3302629 )
1987
9
[Ultrastructural and ultracytochemical characteristics of the terminal villi of the placenta in EPH-toxemia of pregnancy]. ( 3006644 )
1985
10
HLA antigens-antibodies system and its association with severe toxemia of pregnancy. ( 3973430 )
1985
11
Thrombotic thrombocytopenic purpura mimicking toxemia of pregnancy. ( 6541433 )
1984
12
Toxemia of pregnancy masquerading as idiopathic thrombocytopenic purpura. ( 6683829 )
1983
13
Observation of an organism found in patients with gestational trophoblastic disease and in patients with toxemia of pregnancy. ( 6295163 )
1983
14
Observation of an organism found in patients with gestational trophoblastic disease and in patients with toxemia of pregnancy. ( 6312798 )
1983
15
The role of placental urokinase inhibitor in toxemia of pregnancy. ( 6360225 )
1983
16
[Acute choriocapillaris occlusion and Elschnig's spots during a toxemia of pregnancy (author's transl)]. ( 7264211 )
1981
17
Case report: ruptured spleen, placental abruption and toxemia of pregnancy. Simultaneous complications of pregnancy. ( 927413 )
1977
18
Coagulation studies on the peripheral circulation of patients with toxemia of pregnancy: a study for the evaluation of disseminated intravascular coagulation in toxemia. ( 5165542 )
1971
19
Alkaline phosphatase activity in dialysed urine samples from patients with normal pregnancy, toxemia of pregnancy and chronic pyelonephritis. ( 5720439 )
1968
20
CHORIOANGIOMA AND TOXEMIA OF PREGNANCY. ( 14258033 )
1965
21
Severe abruptio placentae, toxemia of pregnancy, and renal biopsy. A clinicopathologic study. ( 5847911 )
1965
22
THE PATHOGENIC ROLE OF FIBRIN DEPOSITION IN THE GLOMERULAR LESIONS OF TOXEMIA OF PREGNANCY. ( 14078004 )
1963
23
Massive cerebral hemorrhage complicating toxemia of pregnancy. ( 13564171 )
1958
24
Hydatidiform mole and toxemia of pregnancy; with unusual late development of lutein cyst. ( 13469897 )
1957
25
Hydatidiform mole and toxemia of pregnancy. ( 13236124 )
1955
26
Cerebral hemorrhage as a complication in toxemia of pregnancy. ( 13138962 )
1953
27
Subhyaloid hemorrhage and exophthalmos due to ruptured intraventricular aneurysm; a case occurring in toxemia of pregnancy. ( 14914266 )
1952
28
Non-erythroblastotic hydrops fetalis recurring in association with toxemia of pregnancy. ( 18105516 )
1948
29
Toxemia of pregnancy and experimental hypertension; the production and the measurement of experimental renal hypertension. ( 20993713 )
1946
30
TOXEMIA OF PREGNANCY IN THE RABBIT : I. CLINICAL MANIFESTATIONS AND PATHOLOGY. ( 19870636 )
1937

Variations for Preeclampsia/eclampsia 1

ClinVar genetic disease variations for Preeclampsia/eclampsia 1:

6 (show top 50) (show all 265)
# Gene Variation Type Significance SNP ID Assembly Location
1 LOC108281140; MEGF6 CM000663.1: g.3411413_3431235dup duplication not provided GRCh38 Chromosome 1, 3494849: 3514671
2 LOC108281140; MEGF6 CM000663.1: g.3411413_3431235dup duplication not provided GRCh37 Chromosome 1, 3411413: 3431235
3 CM000663.1: g.41343608_41378076dup duplication not provided GRCh38 Chromosome 1, 40877936: 40912404
4 CM000663.1: g.41343608_41378076dup duplication not provided GRCh37 Chromosome 1, 41343608: 41378076
5 NC_000001.11: g.96970334_96988991del18658 deletion not provided GRCh38 Chromosome 1, 96970334: 96988991
6 NC_000001.11: g.96970334_96988991del18658 deletion not provided GRCh37 Chromosome 1, 97435890: 97454547
7 NC_000001.11: g.111383531_111391682del8152 deletion not provided GRCh38 Chromosome 1, 111383531: 111391682
8 NC_000001.11: g.111383531_111391682del8152 deletion not provided GRCh37 Chromosome 1, 111926153: 111934304
9 CD160; PDZK1; RNF115 NC_000001.10: g.145625979_145762959del136981 deletion not provided GRCh37 Chromosome 1, 145625979: 145762959
10 KIF26B NM_018012.4(KIF26B): c.1166+53868_1166+59172del deletion not provided GRCh38 Chromosome 1, 245473613: 245478917
11 KIF26B NM_018012.4(KIF26B): c.1166+53868_1166+59172del deletion not provided GRCh37 Chromosome 1, 245636915: 245642219
12 SOX11 NC_000002.11: g.4677905_5958997dup duplication not provided GRCh37 Chromosome 2, 4677905: 5958997
13 NC_000002.12: g.49630800_49638002del7203 deletion not provided GRCh38 Chromosome 2, 49630800: 49638002
14 NC_000002.12: g.49630800_49638002del7203 deletion not provided GRCh37 Chromosome 2, 49857938: 49865140
15 LOC730100 NR_135237.1(LOC730100): n.754-62628_754-62323del deletion not provided rs1553354646 GRCh38 Chromosome 2, 51699461: 51699766
16 LOC730100 NR_135237.1(LOC730100): n.754-62628_754-62323del deletion not provided rs1553354646 GRCh37 Chromosome 2, 51926599: 51926904
17 NC_000002.11: g.89427986_90240473dup duplication not provided GRCh37 Chromosome 2, 89427986: 90240473
18 NC_000002.11: g.89427986_91820358dup duplication not provided GRCh37 Chromosome 2, 89427986: 91820358
19 NC_000002.11: g.90094257_90109261del15005 deletion not provided GRCh37 Chromosome 2, 90094257: 90109261
20 REV1 CM000664.1: g.100055763_100062163dup duplication not provided GRCh38 Chromosome 2, 99439301: 99445701
21 REV1 CM000664.1: g.100055763_100062163dup duplication not provided GRCh37 Chromosome 2, 100055763: 100062163
22 LRP1B NM_018557.2(LRP1B): c.344-65793_344-61550del deletion not provided GRCh38 Chromosome 2, 141316191: 141320434
23 LRP1B NM_018557.2(LRP1B): c.344-65793_344-61550del deletion not provided GRCh37 Chromosome 2, 142073760: 142078003
24 BAZ2B; LOC643072 NM_001282805.1(MARCH7): c.-247472_-1723dup duplication not provided GRCh38 Chromosome 2, 159465277: 159711026
25 BAZ2B; LOC643072 NM_001282805.1(MARCH7): c.-247472_-1723dup duplication not provided GRCh37 Chromosome 2, 160321788: 160567537
26 ACSL3 CM000664.1: g.223798501_223823141dup duplication not provided GRCh38 Chromosome 2, 222933783: 222958423
27 ACSL3 CM000664.1: g.223798501_223823141dup duplication not provided GRCh37 Chromosome 2, 223798501: 223823141
28 TM4SF20 NM_024795.3(TM4SF20): c.-14304_183+492dup duplication not provided GRCh38 Chromosome 2, 227378594: 227393572
29 TM4SF20 NM_024795.3(TM4SF20): c.-14304_183+492dup duplication not provided GRCh37 Chromosome 2, 228243310: 228258288
30 LINC01237; LINC01238; LINC01880; LINC01881; LOC285097 NR_110592.1(LINC01238): n.972-495_131503del deletion not provided GRCh38 Chromosome 2, 241975583: 242106609
31 LINC01237; LINC01238; LINC01880; LINC01881; LOC285097 NR_110592.1(LINC01238): n.972-495_131503del deletion not provided GRCh37 Chromosome 2, 242917734: 243048760
32 ARPP21 CM000665.1: g.35826707_35902885dup duplication not provided GRCh38 Chromosome 3, 35785215: 35861393
33 ARPP21 CM000665.1: g.35826707_35902885dup duplication not provided GRCh37 Chromosome 3, 35826707: 35902885
34 CTDSPL NM_001008392.1(CTDSPL): c.80-8666_80-2299del deletion not provided GRCh38 Chromosome 3, 37938391: 37944758
35 CTDSPL NM_001008392.1(CTDSPL): c.80-8666_80-2299del deletion not provided GRCh37 Chromosome 3, 37979882: 37986249
36 SFMBT1 NM_016329.3(SFMBT1): c.-130-31770_-130-30021del deletion not provided GRCh38 Chromosome 3, 52999279: 53001028
37 SFMBT1 NM_016329.3(SFMBT1): c.-130-31770_-130-30021del deletion not provided GRCh37 Chromosome 3, 53033295: 53035044
38 NC_000003.12: g.65206172_65228858del22687 deletion not provided GRCh38 Chromosome 3, 65206172: 65228858
39 NC_000003.12: g.65206172_65228858del22687 deletion not provided GRCh37 Chromosome 3, 65191847: 65214533
40 NC_000003.12: g.65206172_65230129del23958 deletion not provided GRCh38 Chromosome 3, 65206172: 65230129
41 NC_000003.12: g.65206172_65230129del23958 deletion not provided GRCh37 Chromosome 3, 65191847: 65215804
42 NC_000003.12: g.65206172_65226921del20750 deletion not provided GRCh38 Chromosome 3, 65206172: 65226921
43 NC_000003.12: g.65206172_65226921del20750 deletion not provided GRCh37 Chromosome 3, 65191847: 65212596
44 LINC02018 NC_000003.12: g.75379524_75556006del176483 deletion not provided GRCh38 Chromosome 3, 75379524: 75556006
45 LINC02018 NC_000003.12: g.75379524_75556006del176483 deletion not provided GRCh37 Chromosome 3, 75428675: 75605157
46 FRG2C; LINC00960; LINC02018; MIR1324 NR_031714.1(MIR1324): n.-251239_47012del deletion not provided GRCh38 Chromosome 3, 75379524: 75677774
47 FRG2C; LINC00960; LINC02018; MIR1324 NR_031714.1(MIR1324): n.-251239_47012del deletion not provided GRCh37 Chromosome 3, 75428675: 75726925
48 ADGRG7; TFG CM000665.1: g.100351696_100437892dup duplication not provided GRCh38 Chromosome 3, 100632852: 100719048
49 ADGRG7; TFG CM000665.1: g.100351696_100437892dup duplication not provided GRCh37 Chromosome 3, 100351696: 100437892
50 NC_000003.12: g.149246905_149249548del2644 deletion not provided GRCh38 Chromosome 3, 149246905: 149249548

Expression for Preeclampsia/eclampsia 1

Search GEO for disease gene expression data for Preeclampsia/eclampsia 1.

Pathways for Preeclampsia/eclampsia 1

GO Terms for Preeclampsia/eclampsia 1

Sources for Preeclampsia/eclampsia 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....